Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00899496|
Recruitment Status : Completed
First Posted : May 12, 2009
Last Update Posted : May 30, 2017
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
PURPOSE: This laboratory study is looking at an assay in determining cancer resistance in patients with metastatic cancer and in healthy participants.
|Condition or disease||Intervention/treatment|
|Cancer||Other: immunological diagnostic method Other: physiologic testing|
- Optimize and standardize the in vitro cell kill assay using human white blood cells and human cancer cell lines from patients with metastatic cancer and from healthy participants.
- Determine the results of the in vitro cell kill assay in patients with metastatic cancer and in healthy participants with no history of cancer.
OUTLINE: This is a pilot study.
Peripheral blood is obtained from healthy participants and from cancer patients. Tissue is collected from archived samples. White blood cells are obtained from tissue and blood samples and are assessed by the in vitro cell kill assay.
PROJECTED ACCRUAL: A total of 24 patients and 24 healthy participants will be accrued for this study.
|Study Type :||Observational|
|Actual Enrollment :||54 participants|
|Official Title:||Pilot Study of Cancer Resistance in Humans|
|Actual Study Start Date :||September 2005|
|Actual Primary Completion Date :||October 23, 2009|
|Actual Study Completion Date :||October 23, 2009|
- Cell killing ability (positive or negative) [ Time Frame: Day 180 ]
- Percentage of cells killed [ Time Frame: Day 180 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00899496
|United States, North Carolina|
|Wake Forest University Comprehensive Cancer Center|
|Winston-Salem, North Carolina, United States, 27157-1096|
|Study Chair:||Zheng Cui, PhD||Wake Forest University Health Sciences|